We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

By LabMedica International staff writers
Posted on 18 Apr 2025

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. More...

They are also integral in forensic investigations and biosensing. Fluorophores have been utilized by scientists to highlight cells and tissues under specialized microscopes, making even the smallest details visible. These molecules also play a crucial role in tracking diseases, studying cellular functions, and assisting in the diagnosis of various health conditions. Now, researchers have developed tiny, clay-based materials known as fluorescent polyionic nanoclays, which can be tailored for numerous applications, including improving medical tests.

These fluorescently labeled nanoclays, created by researchers at the University of Missouri-Columbia (Columbia, MO, USA), exhibit an exceptional brightness of 7,000 brightness units when normalized by volume, marking the highest levels ever recorded for a fluorescent material. This increased brightness makes these materials highly effective for sensitive optical detection methods, leading to stronger analytical signals and improved detection. These enhancements open up new possibilities for advanced sensors and contrast agents in medical imaging. Published in Chemistry of Materials, the study emphasizes the versatility of these nanoclays, which can be adapted to a variety of applications. They have a high degree of functionality, allowing for precise control over the number and type of fluorescent molecules attached to their surfaces. This capability provides a flexible platform where the optical and physicochemical properties of the nanoclays can be finely tuned by selecting and attaching specific molecules.

One of the key features of these nanoclays is their ability to be easily customized, making them suitable for diverse applications in different fields. Initial tests suggest that these materials are safe for medical use, potentially enabling doctors to see inside the body with greater clarity. Although fluorescence remains the primary focus of current research, the team plans to further explore the customization of these nanoclays by incorporating other molecules, such as amino acids, antibodies, DNA aptamers, and ligands for selective metal binding. This opens up opportunities for applications beyond just imaging and sensing. These materials could also play a significant role in drug delivery, improving medical tests, monitoring diseases, and aiding in cancer treatment.


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Whole Blood Control
Lyphochek Whole Blood Control
New
Silver Member
Luteinizing Hormone Test
Luteinizing Hormone (LH) Rapid Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Non-coding RNAs CBR3-AS1 and PCA3 can be utilized as therapeutic targets and prognostic biomarkers in gastric cancer (Photo courtesy of Adobe Stock)

Promising Molecular Markers Support Earlier Diagnosis of Gastric Cancer

Late detection continues to make gastric cancer one of the leading causes of cancer-related deaths globally. With improved early detection tools urgently needed, researchers have now identified two long... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: The new technology combines a rapid hemoglobin test with a smartphone app (Photo courtesy of 123RF)

Smartphone-Based Rapid Hemoglobin Test Accurately Detects Colorectal Cancer

Despite the availability of colorectal cancer screening programs, participation remains low, especially for fecal immunochemical tests (FIT), a non-invasive method to detect hidden blood in the stool.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.